Covance: New offering applies Chiltern-developed engagement models

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Image Source)
(Image: Getty/Image Source)

Related tags: Pharmacology, Clinical trial

LabCorp’s Covance has launched a new dedicated offering for biotech, medical device, and diagnostic companies following its purchase of Chiltern in 2017.

These client segments have specific needs for their clinical trials, which can be different from those of larger biopharma companies​,” said Lewis Cameron, head of Global Clinical Development, Covance.

The offering applies “customized engagement models successfully developed by Chiltern​,” he told us.

Chiltern joined Covance, the drug development division of LabCorp, after being acquired in September 2017​ for $1.2bn.

The new dedicated offering, announced Monday, also provides access to additional resources provided by Covance and LabCorp, said Cameron, and includes access to the Covance MarketPlace, the company’s proprietary model for connecting biotech companies with co-development or investment partners.

Cameron explained the addition of Chiltern strengthened Covance’s “focus on the biotech client segment and deepened our therapeutic expertise, particularly in oncology​.”

“Chiltern also brought comprehensive capabilities in medical device development​,” he said, explaining that the company is “pleased​” with the progress of the Chiltern integration to date.

This offering demonstrates how we’re working to translate the powerful combination of Covance and Chiltern to benefit our clients​.”

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us

Products

View more

Webinars